CU20190095A7 - Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias - Google Patents

Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias

Info

Publication number
CU20190095A7
CU20190095A7 CU2019000095A CU20190095A CU20190095A7 CU 20190095 A7 CU20190095 A7 CU 20190095A7 CU 2019000095 A CU2019000095 A CU 2019000095A CU 20190095 A CU20190095 A CU 20190095A CU 20190095 A7 CU20190095 A7 CU 20190095A7
Authority
CU
Cuba
Prior art keywords
compositions
treatment
fused bicyclic
parasitic diseases
bicyclic compounds
Prior art date
Application number
CU2019000095A
Other languages
English (en)
Other versions
CU24543B1 (es
Inventor
Jan Jiricek
Isabelle K Lerario
Fang Liang
Xiaodong Liu
Valentina Molteni
Advait Suresh Nagle
Shuyi Pearly Ng
Maxim Ratnikov
Jeffrey M Smith
Yongping Xie
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CU20190095A7 publication Critical patent/CU20190095A7/es
Publication of CU24543B1 publication Critical patent/CU24543B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

<p>La presente invención proporciona un compuesto de la Fórmula (I);</p> <p>ESPACIO PARA FÓRMULA</p> <p>un método de preparación de los compuestos de la invención. La presente invención además proporciona una combinación de agentes farmacológicamente activos y una composición farmacéutica.</p>
CU2019000095A 2017-05-31 2018-05-29 Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias CU24543B1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762513211P 2017-05-31 2017-05-31
US201762581919P 2017-11-06 2017-11-06
PCT/IB2018/053818 WO2018220531A1 (en) 2017-05-31 2018-05-29 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases

Publications (2)

Publication Number Publication Date
CU20190095A7 true CU20190095A7 (es) 2020-10-20
CU24543B1 CU24543B1 (es) 2021-08-06

Family

ID=62749123

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2019000095A CU24543B1 (es) 2017-05-31 2018-05-29 Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias

Country Status (26)

Country Link
US (2) US11384078B2 (es)
EP (1) EP3630771B1 (es)
JP (1) JP7187490B2 (es)
KR (1) KR20200010275A (es)
CN (1) CN110678468B (es)
AR (1) AR111826A1 (es)
AU (1) AU2018276190B2 (es)
BR (1) BR112019024804A2 (es)
CA (1) CA3060990A1 (es)
CL (1) CL2019003467A1 (es)
CO (1) CO2019013254A2 (es)
CR (1) CR20190545A (es)
CU (1) CU24543B1 (es)
DO (1) DOP2019000299A (es)
EC (1) ECSP19084722A (es)
ES (1) ES2927207T3 (es)
IL (1) IL270927B (es)
JO (1) JOP20190278A1 (es)
MA (1) MA50495A (es)
MX (1) MX2019014321A (es)
PE (1) PE20201148A1 (es)
PH (1) PH12019502652A1 (es)
RU (1) RU2738647C1 (es)
TW (1) TW201902894A (es)
UY (1) UY37745A (es)
WO (1) WO2018220531A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190278A1 (ar) * 2017-05-31 2019-11-28 Novartis Ag مركبات 5، 6-ثنائية الحلقة مندمجة وتركيبات لعلاج الأمراض الطفيلية
EP4136066A1 (en) * 2020-04-17 2023-02-22 DSM IP Assets B.V. A process for preparation of substituted enamine compounds
EP4155302A4 (en) * 2020-06-23 2023-11-22 Shanghai Meiyue Biotech Development Co., Ltd. METHOD FOR PREPARING A CONDENSED PYRAZOLE-TYPE COMPOUND

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10053275A1 (de) 2000-10-27 2002-05-02 Dresden Arzneimittel Neue 7-Azaindole, deren Verwendung als Inhibitoren der Phosphodiesterase 4 und Verfahren zu deren Herstellung
CL2004000398A1 (es) 2003-02-27 2005-03-18 Uriach Y Compania S A J Compuestos derivados de pirazolopiridinas, sus sales; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar enfermedades mediadas por quinasas p38, en especial por citocinas, tnf-alfa, il-1, il-6 y/o il-8, tales como enfermedad
AR085410A1 (es) 2011-02-25 2013-10-02 Dow Agrosciences Llc Derivados de pirazol heteroaril-sustituidos, composiciones pesticidas que los comprenden y su uso en el control de plagas
WO2013067302A1 (en) * 2011-11-04 2013-05-10 Glaxosmithkline Intellectual Property (No. 2) Limited Method of treatment
WO2013106254A1 (en) * 2012-01-11 2013-07-18 Dow Agrosciences Llc Pesticidal compositions and processes related thereto
ME03042B (me) 2012-11-19 2018-10-20 Novartis Ag Jedinjenja i kompozicije za tretman parazitskih oboljenja
UY35400A (es) * 2013-03-15 2014-10-31 Novartis Ag Compuestos y composiciones para el tratamiento de enfermedades parasitarias
US9186361B2 (en) * 2013-03-15 2015-11-17 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
BR112016014004B1 (pt) 2013-12-19 2022-11-01 Novartis Ag Compostos para tratamento de doenças parasíticas, seus usos, e composições farmacêuticas
CN107207497A (zh) 2014-12-02 2017-09-26 拜耳作物科学股份公司 作为害虫防治剂的双环化合物
CN107635984B (zh) 2015-03-11 2021-04-13 Fmc公司 杂环取代的二环唑杀有害生物剂
TW201713661A (zh) 2015-05-29 2017-04-16 葛蘭素史克智慧財產發展有限公司 化合物
JP6838045B2 (ja) 2015-08-07 2021-03-03 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 化合物
CN114984003A (zh) * 2016-05-03 2022-09-02 拜耳制药股份公司 芳族磺酰胺衍生物
JOP20190278A1 (ar) * 2017-05-31 2019-11-28 Novartis Ag مركبات 5، 6-ثنائية الحلقة مندمجة وتركيبات لعلاج الأمراض الطفيلية

Also Published As

Publication number Publication date
PE20201148A1 (es) 2020-10-26
KR20200010275A (ko) 2020-01-30
AU2018276190A1 (en) 2019-11-07
EP3630771A1 (en) 2020-04-08
CL2019003467A1 (es) 2020-03-13
CU24543B1 (es) 2021-08-06
DOP2019000299A (es) 2019-12-15
ES2927207T3 (es) 2022-11-03
JOP20190278A1 (ar) 2019-11-28
CR20190545A (es) 2020-01-15
TW201902894A (zh) 2019-01-16
MX2019014321A (es) 2020-02-05
CN110678468B (zh) 2022-07-29
CO2019013254A2 (es) 2020-01-17
CN110678468A (zh) 2020-01-10
RU2738647C1 (ru) 2020-12-15
ECSP19084722A (es) 2019-12-27
PH12019502652A1 (en) 2020-07-13
US11384078B2 (en) 2022-07-12
IL270927B (en) 2022-01-01
AR111826A1 (es) 2019-08-21
IL270927A (en) 2020-01-30
BR112019024804A2 (pt) 2020-06-09
US20220324863A1 (en) 2022-10-13
CA3060990A1 (en) 2018-12-06
MA50495A (fr) 2021-04-28
UY37745A (es) 2019-01-02
JP2020521775A (ja) 2020-07-27
AU2018276190B2 (en) 2020-05-14
EP3630771B1 (en) 2022-06-29
WO2018220531A1 (en) 2018-12-06
US20200109142A1 (en) 2020-04-09
JP7187490B2 (ja) 2022-12-12

Similar Documents

Publication Publication Date Title
CO2018011064A2 (es) Inhibidores de bromodominios
SV2016005351A (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
EA202090688A1 (ru) Бис-амидные соединения, активирующие саркомер, и варианты их применения
CY1124251T1 (el) Παραγωγα καρβοξαμιδιου
BR112017016817A2 (pt) derivados heterocíclicos formilados como inibidores de fgfr4
CO2018004572A2 (es) Inhibidores de calicreína plasmática humana
EA201990765A1 (ru) Азаиндазольные соединения для применения при повреждениях сухожилий и/или связок
TN2016000491A1 (en) Carboxamide derivatives.
CU24543B1 (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
PH12019500849A1 (en) Naphthyridinone derivatives and their use inthe treatment of arrhythmia
DOP2020000100A (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3
EA201691058A1 (ru) Производные пирролопирролона и их применение для лечения заболеваний
EA201990766A1 (ru) Индазольные соединения для применения при повреждениях сухожилий и/или связок
EA202192760A1 (ru) Трициклические соединения
EA201992577A1 (ru) 5,6-конденсированные бициклические соединения и композиции для лечения паразитарных заболеваний
CO2022004768A2 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
UY33857A (es) Compuestos de tiofeno 2,3,5-trisustituidos y usos de los mismos.
PH12016502247A1 (en) Carboxamide derivatives